Ever Supreme Bio Technology Co

Ever Supreme Bio Technology Co EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Ever Supreme Bio Technology Co (6712.TWO) as of Oct 18, 2026 is 28.13. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 34.34 — a change of -18.08% (lower).

EV/FCF

28.13

YoY

-18.08%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Ever Supreme Bio Technology Co is 2025 28.13 . EV/FCF (Enterprise Value to Free Cash Flow) of Ever Supreme Bio Technology Co was 2024 34.34 . It decreases by -18.08% lower compared to the previous year.

The Ever Supreme Bio Technology Co EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-145.49 TWD
Jan 1, 2019
-111.23 TWD
Jan 1, 2020
-73.03 TWD
Jan 1, 2021
103.91 TWD
Jan 1, 2022
43.60 TWD
Jan 1, 2023
32.69 TWD
Jan 1, 2024
34.34 TWD
Jan 1, 2025
28.13 TWD
The Ever Supreme Bio Technology Co EV/FCF history
YEAREV/FCFYoY
28.13-18.08%
34.34+5.03%
32.69-25.02%
43.60-58.04%
103.91-242.29%
-73.03-34.35%
-111.23-23.55%
-145.49-61.04%
-373.47—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Ever Supreme Bio Technology Co Stock analysis

What does Ever Supreme Bio Technology Co do? Ever Supreme Bio Technology Co Ltd is a biotechnology company based in Taichung, Taiwan, operating within the healthcare sector. The company has 8 employees and went public on October 26, 2018. It focuses on the research, development, and sale of stem cell products. The company's website is https://www.ever-supreme.com.tw/. Ever Supreme Bio Technology Co Ltd is engaged in the development of stem cell-based therapies, with specific products including ADCV01, a dendritic cell tumor vaccine currently in Phase II clinical trials in Taiwan. The company also develops UMSC01, a human allogeneic umbilical cord stem cell product intended for the treatment of myocardial infarction. UMSC01 is approved for Phase I clinical trials by the U.S. Food and Drug Administration (FDA) and is undergoing regulatory processes in Taiwan. Additionally, the company is involved in the development of stem cell treatments for acute ischemic stroke, with clinical Phase I trials pending in the United States. The company has plans to expand its product portfolio to include mesenchymal stem cells for multiple sclerosis treatment. Ever Supreme Bio Technology Co Ltd is listed on the Taiwan Stock Exchange under ticker 6712.TWO with ISIN TW0006712003. The company's operations are centered around innovative biotechnology solutions aimed at addressing critical healthcare needs. Ever Supreme Bio Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ever Supreme Bio Technology Co stock

EV/FCF (Enterprise Value to Free Cash Flow) of Ever Supreme Bio Technology Co is 28.13 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Ever Supreme Bio Technology Co changed from 34.34 to 28.13, representing a -18.08% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Ever Supreme Bio Technology Co since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Ever Supreme Bio Technology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Ever Supreme Bio Technology Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Ever Supreme Bio Technology Co